PHILADELPHIA , Sept. 2, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Altimmune Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") on behalf of investors who purchased or otherwise acquired publicly traded securities of Altimmune between August 10, 2023 through June 25, 2025 (the "Class Period").

Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025 , seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE .

Altimmune, headquartered in Gaithersburg, Maryland , is a clinical-stage biopharmaceutical company focused on developing therapeutics for obesity and liver disease, including MASH (metabolic dys

See Full Page